Latest RNA interference Stories

LAUSANNE, Switzerland and DRESDEN, Germany, May 23, 2013 /PRNewswire/ -- Cenix BioScience, a leading preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced...

AMSTERDAM, The Netherlands, May 21, 2013 /PRNewswire/ -- uniQure B.V., a leader in the field of human gene therapy, today announced that with its consortium partners it is to receive a EUR 2.5 million Eurostars grant to develop an RNA interference (RNAi) gene therapy for Huntington's disease. The consortium is a pan-European collaboration consisting of uniQure as the coordinator, Lausanne University Hospital, Switzerland, University Medical Center Gottingen, Germany, and...

WESTBOROUGH, Mass., May 20, 2013 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the Jefferies 2013 Global Healthcare Conference on Thursday, June 6, 2013 at 10:00am EDT. Dr. Cauwenbergh will...

JUPITER, Fla., April 30, 2013 /PRNewswire/ -- SMaRT Therapeutics, Inc., a leading biotechnology company focused on the development of small-molecule drugs that target and modulate RNA, announced the appointment of Dr. John H. Abeles to its Advisory Board. Dr. Abeles has had a long and distinguished career in the biotechnology and pharmaceutical industries. He practiced medicine in London before serving as a Senior Medical Executive with Sterling Drug, Pfizer and Revlon Healthcare....

Altogen Labs is a GLP compliant laboratory that provides preclinical research and biology contract research services (CRO). Altogen Labs now offers wide variety of preclinical CRO services, including drug development, generation of stable cell lines, RNAi gene silencing and in vivo research services (xenograft, in vivo siRNA delivery), pharm/tox assays (IC50), cell banking, and ELISA assay development. Austin, TX (PRWEB) April 26, 2013 Altogen Labs, a biotechnology company focused on...

SYDNEY, April 15, 2013 /PRNewswire/ -- RNAi-based therapeutics company Benitec Biopharma Limited (ASX Code: BLT) today announced the selection of the University of California, San Diego (UCSD), Health Sciences as the second site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C infections (HCV). Benitec previously announced the selection of Duke Clinical Research Unit as the other site. TT-034 is being developed as a potential "one-shot-cure" for HCV. A...

Study of RNA interference drug presented at AACR Annual Meeting 2013 The safety and preliminary efficacy of a new class of tumor fighting drugs were reported today by Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials and the Translational Genomics Research Institute (TGen). Early results from the phase I, first in-human study of an RNA interference (RNAi) drug were announced during the American Association for Cancer Research (AACR) Annual Meeting 2013, April 6-10,...

SYDNEY and DURHAM, N.C., March 21, 2013 /PRNewswire/ -- RNAi-based therapeutics company Benitec Biopharma Limited (ASX Code: BLT) today announced the selection of the Duke Clinical Research Unit, the early phase unit of the Duke Clinical Research Institute (DCRI), Durham, North Carolina, USA as a site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C. TT-034 is being developed as a potential "one-shot-cure" for Hepatitis C (HCV). "We are very excited to be...

Ability to tune gene activity will permit refined research for drug resistance, cancer Scientists who built a synthetic gene circuit that allowed for the precise tuning of a gene's expression in yeast have now refined this new research tool to work in human cells, according to research published online in Nature Communications. "Using this circuit, you can turn a gene from completely off to completely on and anywhere between those two extremes in each cell at once. It's a nice tool if...

CAMBRIDGE, England, Jan. 31, 2013 /PRNewswire/ -- One of the most innovative biotechnologies of the last decade has recently been developed. SINEUP allows scientists, for the first time, to target individual genes in cells to knockup, or increase, the amount of protein they make. The technique will improve Protein manufacture, analyse the function of genes and engineer improved cell function. This novel technology is based on pioneering research in the lab of Dr Stefano...